|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
DE3587657D1
(de)
|
1984-01-30 |
1993-12-23 |
Imp Cancer Res Tech |
Verbesserungen an wachstumsfaktoren.
|
|
US5401638A
(en)
|
1986-06-04 |
1995-03-28 |
Oncogene Science, Inc. |
Detection and quantification of neu related proteins in the biological fluids of humans
|
|
US4968603A
(en)
|
1986-12-31 |
1990-11-06 |
The Regents Of The University Of California |
Determination of status in neoplastic disease
|
|
CA1339946C
(en)
|
1987-03-31 |
1998-07-07 |
Michael J. Griffith |
Ultrapurification process for polypeptides
|
|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
US5720937A
(en)
|
1988-01-12 |
1998-02-24 |
Genentech, Inc. |
In vivo tumor detection assay
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
EP0474727B1
(en)
|
1989-05-19 |
1997-07-23 |
Genentech, Inc. |
Her2 extracellular domain
|
|
DE68926248T2
(de)
|
1989-09-29 |
1996-12-19 |
Oncogene Science Inc |
p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen
|
|
US5183884A
(en)
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
|
IL101943A0
(en)
|
1991-05-24 |
1992-12-30 |
Genentech Inc |
Structure,production and use of heregulin
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
DE69233254T2
(de)
|
1991-06-14 |
2004-09-16 |
Genentech, Inc., South San Francisco |
Humanisierter Heregulin Antikörper
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
JP3951062B2
(ja)
|
1991-09-19 |
2007-08-01 |
ジェネンテック・インコーポレーテッド |
少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
CN102416176A
(zh)
|
1995-07-27 |
2012-04-18 |
基因技术股份有限公司 |
稳定等渗的冻干蛋白质制剂
|
|
US5783186A
(en)
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
|
US7371376B1
(en)
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
|
EP0852951A1
(de)
|
1996-11-19 |
1998-07-15 |
Roche Diagnostics GmbH |
Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
|
|
ES2293661T3
(es)
|
1996-11-27 |
2008-03-16 |
Genentech, Inc. |
Purificacion por afinidad de polipeptido en una matriz de proteinas a.
|
|
US5994071A
(en)
|
1997-04-04 |
1999-11-30 |
Albany Medical College |
Assessment of prostate cancer
|
|
ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
|
DE69938923D1
(de)
|
1998-03-27 |
2008-07-31 |
Genentech Inc |
Synergie zwischen apo-2 ligand und antikörper gegen her-2
|
|
KR101036414B1
(ko)
|
1998-05-06 |
2011-05-23 |
제넨테크, 인크. |
이온 교환 크로마토그래피에 의한 단백질 정제 방법
|
|
US6573043B1
(en)
|
1998-10-07 |
2003-06-03 |
Genentech, Inc. |
Tissue analysis and kits therefor
|
|
WO2000069460A1
(en)
|
1999-05-14 |
2000-11-23 |
Genentech, Inc. |
TREATMENT WITH ANTI-ErbB2 ANTIBODIES
|
|
US20040013667A1
(en)
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US20030086924A1
(en)
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
|
KR100754049B1
(ko)
|
1999-06-25 |
2007-08-31 |
제넨테크, 인크. |
전립선암을 치료하기 위한 약제 제조에 사용되는 항-ErbB2 항체 및 조성물
|
|
KR20090126330A
(ko)
|
1999-08-27 |
2009-12-08 |
제넨테크, 인크. |
항-ＥｒｂＢ2 항체 투여 치료 방법
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
US6632979B2
(en)
|
2000-03-16 |
2003-10-14 |
Genentech, Inc. |
Rodent HER2 tumor model
|
|
US20200048362A1
(en)
|
2000-03-16 |
2020-02-13 |
Immunogen, Inc. |
Methods of treatment using anti-erbb antibody-maytansinoid conjugates
|
|
KR20080038458A
(ko)
|
2000-05-19 |
2008-05-06 |
제넨테크, 인크. |
ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석
|
|
US6984494B2
(en)
|
2000-08-15 |
2006-01-10 |
Genentech, Inc. |
Analytical method
|
|
WO2002072636A2
(en)
|
2000-12-28 |
2002-09-19 |
Altus Biologics Inc. |
Crystals of whole antibodies and fragments thereof and methods for making and using them
|
|
US6695940B2
(en)
|
2001-04-05 |
2004-02-24 |
Alan D. Devoe |
Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells
|
|
EP1300146A1
(en)
|
2001-10-03 |
2003-04-09 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition for the treatment of animal mammary tumors
|
|
US20040048525A1
(en)
|
2002-01-28 |
2004-03-11 |
Sagucio Esteban N. |
Watercycle for wet rider
|
|
JP2005522514A
(ja)
|
2002-04-10 |
2005-07-28 |
ジェネンテック・インコーポレーテッド |
抗ｈｅｒ２抗体改変体
|
|
US6982719B2
(en)
|
2002-07-15 |
2006-01-03 |
Sun Microsystems, Inc. |
Switching sample buffer context in response to sample requests for real-time sample filtering and video generation
|
|
HUP0600340A3
(en)
|
2002-07-15 |
2011-06-28 |
Genentech Inc |
Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
|
|
US7129840B2
(en)
|
2002-09-03 |
2006-10-31 |
Ricoh Company, Ltd. |
Document security system
|
|
WO2004024866A2
(en)
|
2002-09-11 |
2004-03-25 |
Genentech, Inc. |
Protein purification
|
|
EP1572972A4
(en)
|
2002-11-21 |
2007-11-21 |
Genentech Inc |
THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES
|
|
TW555245U
(en)
|
2003-01-29 |
2003-09-21 |
Hon Hai Prec Ind Co Ltd |
Cable connector assembly
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
SG177008A1
(en)
|
2003-03-05 |
2012-01-30 |
Halozyme Inc |
Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
|
|
US20050025753A1
(en)
|
2003-04-30 |
2005-02-03 |
Wei Han |
Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells
|
|
LT3095793T
(lt)
|
2003-07-28 |
2020-07-10 |
Genentech, Inc. |
Baltymo a išplovimo sumažinimas afininės baltymo a chromatografijos metu
|
|
CA2563341C
(en)
|
2004-04-08 |
2014-10-21 |
David B. Agus |
Erbb antagonists for pain therapy
|
|
US7195440B2
(en)
|
2004-05-27 |
2007-03-27 |
Lambert Charles F |
Agricultural silo auger system apparatus and method
|
|
BRPI0510883B8
(pt)
|
2004-06-01 |
2021-05-25 |
Genentech Inc |
composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
|
|
SV2006002143A
(es)
|
2004-06-16 |
2006-01-26 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del cancer resistente al platino
|
|
KR20180004850A
(ko)
|
2004-07-22 |
2018-01-12 |
제넨테크, 인크. |
Ｈｅｒ２ 항체 조성물
|
|
US20060067930A1
(en)
|
2004-08-19 |
2006-03-30 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
ZA200704796B
(en)
|
2004-12-07 |
2008-11-26 |
Genentech Inc |
Selecting patients for therapy with a HER inhibitor
|
|
PL1846030T3
(pl)
|
2005-01-21 |
2019-05-31 |
Genentech Inc |
Ustalone dawkowanie przeciwciał her
|
|
EP3195879A1
(en)
|
2005-02-23 |
2017-07-26 |
Genentech, Inc. |
Extending time to disease progression or survival in cancer patients
|
|
US20060204505A1
(en)
|
2005-03-08 |
2006-09-14 |
Sliwkowski Mark X |
Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
|
|
US20060212956A1
(en)
|
2005-03-14 |
2006-09-21 |
Genentech, Inc. |
Animal model of ligand activated HER2 expressing tumors
|
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
|
|
US20070009976A1
(en)
|
2005-07-06 |
2007-01-11 |
Helmut Lenz |
Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
|
|
PE20070207A1
(es)
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
|
US7700299B2
(en)
|
2005-08-12 |
2010-04-20 |
Hoffmann-La Roche Inc. |
Method for predicting the response to a treatment
|
|
WO2007067597A2
(en)
|
2005-12-05 |
2007-06-14 |
Trinity Biosystems, Inc. |
Methods and compositions for needleless delivery of binding partners
|
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
|
WO2007145862A2
(en)
|
2006-06-05 |
2007-12-21 |
Genentech, Inc. |
Extending survival of cancer patients with elevated levels of egf or tgf-alpha
|
|
MY150756A
(en)
|
2006-08-21 |
2014-02-28 |
Hoffmann La Roche |
Tumor theraphy with an anti-vegf antibody
|
|
WO2008031531A1
(en)
|
2006-09-15 |
2008-03-20 |
F. Hoffmann-La Roche Ag |
Tumor therapy with a combination of anti-her2 antibodies
|
|
WO2008109440A2
(en)
|
2007-03-02 |
2008-09-12 |
Genentech, Inc. |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
|
EP1997534A1
(en)
|
2007-05-31 |
2008-12-03 |
Pierre Fabre Medicament |
Cancer treatment combination therapy comprising vinflunine and trastuzumab
|
|
US8529901B2
(en)
|
2007-06-06 |
2013-09-10 |
Hoffmann-La Roche, Inc. |
Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
|
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
EP2592156B1
(en)
|
2007-06-08 |
2016-04-20 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
KR101584823B1
(ko)
|
2007-09-12 |
2016-01-22 |
제넨테크, 인크. |
포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법
|
|
PL2840090T3
(pl)
|
2007-10-30 |
2018-07-31 |
Genentech, Inc. |
Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
WO2009111707A1
(en)
|
2008-03-06 |
2009-09-11 |
Genentech, Inc. |
Combination therapy with c-met and her antagonists
|
|
NZ621433A
(en)
|
2008-03-18 |
2015-10-30 |
Genentech Inc |
Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
|
|
US9235334B2
(en)
|
2008-05-09 |
2016-01-12 |
Genesis Industries, Llc |
Managing landbases and machine operations performed thereon
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
|
WO2010136569A1
(en)
|
2009-05-29 |
2010-12-02 |
F. Hoffmann-La Roche Ag |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
|
US9345661B2
(en)
*
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
CN103476407A
(zh)
|
2010-12-09 |
2013-12-25 |
霍夫曼-拉罗奇有限公司 |
用帕利他赛和曲妥珠单抗-mcc-dm1治疗her2阳性癌症
|
|
JP6385060B2
(ja)
|
2011-03-07 |
2018-09-05 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
治療的に活性な抗体のインビボにおける選択
|
|
JP2012228007A
(ja)
*
|
2011-04-15 |
2012-11-15 |
Asmo Co Ltd |
バスバー装置、ステータ、モータ及びステータの製造方法
|
|
ES3023516T3
(en)
|
2011-10-14 |
2025-06-02 |
Hoffmann La Roche |
Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
|
|
EP2788500A1
(en)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
|
WO2013096812A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
|
KR101915942B1
(ko)
|
2012-06-08 |
2018-11-06 |
에프. 호프만-라 로슈 아게 |
암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
|
|
CN102961745B
(zh)
*
|
2012-09-27 |
2015-02-18 |
苏州康聚生物科技有限公司 |
抗体组合物制剂及其应用
|
|
CA2889298C
(en)
|
2012-11-30 |
2024-01-02 |
Anton Belousov |
Identification of patients in need of pd-l1 inhibitor cotherapy
|
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
|
CA2907776C
(en)
|
2013-04-16 |
2020-04-14 |
Genentech, Inc. |
Pertuzumab variants and evaluation thereof
|
|
CN112353943A
(zh)
|
2013-12-17 |
2021-02-12 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法
|
|
KR20160141857A
(ko)
|
2014-04-25 |
2016-12-09 |
제넨테크, 인크. |
트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
|
|
CA2955445A1
(en)
*
|
2014-07-17 |
2016-01-21 |
Brian J. Czerniecki |
Manufacturing of multi-dose injection ready dendritic cell vaccines and combination therapy for blocking her2 and her3
|
|
WO2016044334A1
(en)
|
2014-09-15 |
2016-03-24 |
Genentech, Inc. |
Antibody formulations
|
|
RU2727663C2
(ru)
|
2014-09-17 |
2020-07-22 |
Дженентек, Инк. |
Иммуноконъюгаты, содержащие антитела против her2 и пирролбензодиазепины
|
|
CN104784105A
(zh)
*
|
2015-04-17 |
2015-07-22 |
北京大学 |
一种单克隆抗体药物的凝胶组合物
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
EP3267657A1
(de)
|
2016-07-06 |
2018-01-10 |
Siemens Aktiengesellschaft |
Netzwerksystem, cloud-anschluss und verfahren zur identifikation von netzwerkgeräten
|
|
EP3534948A1
(en)
|
2016-11-04 |
2019-09-11 |
Genentech, Inc. |
Treatment of her2-positive breast cancer
|
|
CA3046092A1
(en)
|
2016-12-28 |
2018-07-05 |
Genentech, Inc. |
Treatment of advanced her2 expressing cancer
|
|
CN117752782A
(zh)
|
2017-01-17 |
2024-03-26 |
豪夫迈·罗氏有限公司 |
皮下her2抗体配制剂
|
|
KR20190096384A
(ko)
|
2017-03-02 |
2019-08-19 |
제넨테크, 인크. |
Her2-양성 유방암 어쥬번트 치료
|
|
EP3615695A1
(en)
|
2017-04-24 |
2020-03-04 |
Genentech, Inc. |
Erbb2/her2 mutations in the transmebrane or juxtamembrane domain
|
|
IL299376A
(en)
|
2020-06-29 |
2023-02-01 |
Genentech Inc |
Fixed dose combination of pertuzumab plus transtuzumab
|
|
WO2022013189A1
(en)
|
2020-07-14 |
2022-01-20 |
F. Hoffmann-La Roche Ag |
Assays for fixed dose combinations
|
|
EP4259662A1
(en)
|
2020-12-11 |
2023-10-18 |
Genentech, Inc. |
Combination therapies for treatment of her2 cancer
|